Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kønsforskelle i reaktionen på afholdenhed fra alkohol. (SPAR)

9. november 2026 opdateret af: Martin Plawecki, Indiana University

In laboratory animals, repeated cycles of abstinence from and return to alcohol drinking can lead to changes in alcohol intake. In a study of the effect of abstinence on drinking in humans, the investigators found evidence that abstinence affects drinking differently in women compared to men. In the present study, the investigators propose to study how men and women respond to abstinence, and whether this information can be used to improve intervention and prevention strategies.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Women and men differ in how quickly they progress from social to problematic alcohol drinking. In laboratory animals, short-term abstinence increases alcohol consumption, with repeated deprivations leading to disordered drinking. In a preliminary study, the investigators found that men and women differed in how their motivation to drink alcohol changed after a short period of abstinence. The investigators hypothesize that this difference may affect their transition to alcohol use disorders. The objectives of this application are to characterize the human post abstinence response, and use identical alcohol exposures to study the mechanisms underlying identified sex differences. In addition, the investigators will complete a 2 year prospective study of natural drinking patterns to assess how self-reported abstinence intervals influence drinking trajectories. The long-term goal of this project is to inform alcohol use disorder treatment and to design and test novel interventions using the laboratory model of post-abstinence response. There is a critical unfilled need to understand sex differences in disease progression, and this lab-based assessment coupled to longitudinal follow-up provides the rigorous experimental design to begin to meet that need. This project will increase scientific knowledge by advancing the translation between preclinical and clinical models, eventually informing sex-specific intervention and prevention strategies for problematic drinking and establishing a model to test those interventions..

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

160

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Martin H Plawecki, MD, PhD
        • Ledende efterforsker:
          • Melissa A Cyders, PhD
        • Underforsker:
          • Wei Wu, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 35 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Moderate social drinkers
  • Able to understand/complete questionnaires and procedures in English
  • Body mass index (BMI) between 18.5 and 32 kg/m2
  • Have venous access sufficient to allow blood sampling

Exclusion Criteria:

  • Pregnant or breast-feeding women, or women who intend to become pregnant
  • Do not attest to using accepted forms of birth control for the infusion phase of the study
  • Current treatment for, or desire to be treated for, any substance use disorder or court ordered to not drink alcohol
  • History of significant adverse reaction to alcohol
  • Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety
  • Medications (past 30 days) that could influence data or participant safety (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by investigators
  • DSM 5 Disorders (non AUD) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness
  • Positive breath alcohol reading on arrival at any study visit
  • Actively suicidal (for example, any suicide attempts within the past year or any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the investigator
  • Any condition for which the principal investigators determine it is unsafe or not prudent to enroll

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Free access alcohol self-administration

During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking

Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.

Andre navne:
  • 6,0 & (v/V) ethanolopløsning
Eksperimentel: Clamped alcohol exposure

A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.

Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.

Andre navne:
  • 6,0 & (v/V) ethanolopløsning

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sex differences in the effect of abstinence on alcohol self-administration.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence on intravenous alcohol intake will be compared in men and women.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence
The role of changes in alcohol elimination on sex differences in response to abstinence.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence from alcohol on alcohol elimination in men and women will be assessed using an iv alcohol infusion clamp.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Response to abstinence as a predictor of alcohol risk in women and men.
Tidsramme: 2 years

For both Arm 1 and Arm 2, daily alcohol consumption will be surveyed every 2 months for 2 years following the laboratory sessions. Self-imposed periods of abstinence will be assessed to determine if subsequent daily alcohol intake increases or decreases, and to determine if men and women differ in the effect of abstinence on drinking.

2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Martin H Plawecki, MD, PhD, Psychiatry, Indiana University School of Medicine
  • Ledende efterforsker: Melissa A Cyders, PhD, Psychology, Indiana University-Purdue University at Indianapolis

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. april 2019

Primær færdiggørelse (Anslået)

28. februar 2027

Studieafslutning (Anslået)

28. februar 2029

Datoer for studieregistrering

Først indsendt

12. november 2018

Først indsendt, der opfyldte QC-kriterier

30. januar 2019

Først opslået (Faktiske)

1. februar 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1809467722
  • R01AA027236-05 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data, and develop a data-sharing agreement.

IPD-delingstidsramme

After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

IPD-delingsadgangskriterier

On request to the PIs

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .